OPEN ACCESS

ORIGINAL ARTICLE

SWI/SNF component *ARID1A* restrains pancreatic neoplasia formation

Sam C Wang,^{1,2} Ibrahim Nassour,^{1,2} Shu Xiao,² Shuyuan Zhang,² Xin Luo,^{2,3} Jeon Lee,³ Lin Li,² Xuxu Sun,² Liem H Nguyen,^{2,4} Jen-Chieh Chuang,² Lan Peng,⁵ Scott Daigle,⁶ Jeanne Shen,⁷ Hao Zhu²

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2017-315490>).

For numbered affiliations see end of article.

Correspondence to

Dr Hao Zhu, Children's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX USA ; hao.zhu@utsouthwestern.edu

SCW and IN contributed equally.

Received 17 October 2017

Revised 24 August 2018

Accepted 28 August 2018

Published Online First

12 October 2018

ABSTRACT

Objective *ARID1A* is commonly mutated in pancreatic ductal adenocarcinoma (PDAC), but the functional effects of *ARID1A* mutations in the pancreas are unclear. Understanding the molecular mechanisms that drive PDAC formation may lead to novel therapies.

Design Concurrent conditional *Arid1a* deletion and *Kras* activation mutations were modelled in mice. Small-interfering RNA (siRNA) and CRISPR/Cas9 were used to abrogate *ARID1A* in human pancreatic ductal epithelial cells.

Results We found that pancreas-specific *Arid1a* loss in mice was sufficient to induce inflammation, pancreatic intraepithelial neoplasia (PanIN) and mucinous cysts. Concurrent *Kras* activation accelerated the development of cysts that resembled intraductal papillary mucinous neoplasm. Lineage-specific *Arid1a* deletion confirmed compartment-specific tumour-suppressive effects. Duct-specific *Arid1a* loss promoted dilated ducts with occasional cyst and PDAC formation. Heterozygous acinar-specific *Arid1a* loss resulted in accelerated PanIN and PDAC formation with worse survival. RNA-seq showed that *Arid1a* loss induced gene networks associated with *Myc* activity and protein translation. *ARID1A* knockdown in human pancreatic ductal epithelial cells induced increased MYC expression and protein synthesis that was abrogated with MYC knockdown. ChIP-seq against H3K27ac demonstrated an increase in activated enhancers/promoters.

Conclusions *Arid1a* suppresses pancreatic neoplasia in a compartment-specific manner. In duct cells, this process appears to be associated with MYC-facilitated protein synthesis.

Significance of this study**What is already known on this subject?**

- Intraductal papillary mucinous neoplasms (IPMN) and pancreatic intraepithelial neoplasia (PanIN) are precursors to pancreatic ductal adenocarcinoma (PDAC).
- Understanding the molecular mechanisms that drive precursor formation and progression can improve PDAC outcomes.
- *ARID1A* is frequently mutated in PDAC.
- *Arid1a* loss in mice leads to IPMN formation that may be mediated by *Sox9* and the mTor (mammalian target of rapamycin) pathway.

What are the new findings?

- Duct-specific *Arid1a* loss induces duct enlargement and tumourigenesis.
- Acinar-specific *Arid1a* heterozygous deletion results in accelerated PanIN formation and worse outcomes.
- *ARID1A* loss in cultured pancreatic duct cells leads to MYC overexpression and increased protein synthesis.
- *ARID1A* deletion in cultured pancreatic duct cells leads to broadly increased enhancer/promoter histone marks.

How might it impact on clinical practice in the foreseeable future?

- Insights into the mechanisms that drive premalignant PDAC lesions may lead to novel therapeutic strategies against this lethal disease.

BACKGROUND

Pancreatic ductal adenocarcinomas (PDAC) can arise out of multiple types of precursor lesions such as pancreatic intraepithelial neoplasia (PanIN) or intraductal papillary mucinous neoplasms (IPMNs).¹ Large-scale sequencing studies have defined the genomic profile of PDAC being dominated by mutations in *KRAS*, *TP53*, *SMAD4* and *CDKN2A* followed by a 'long tail' of the remaining mutations that occur in 10% or less of samples.^{2,3} The most common of these mutations include *ARID1A*, which is also altered in 10% of IPMN.^{4,5}

ARID1A is part of the SWI/SNF complex, which is a multisubunit complex that remodels chromatin by shifting, inserting or evicting nucleosomes in an

ATP-dependent manner.^{6–8} Combinatorial assembly of subunits provides the SWI/SNF complex tissue and temporal specificity in gene regulatory functions that may be activating or repressive.⁸ *ARID1A* is thought to modulate the chromatin remodelling activity of the SWI/SNF complex through direct interactions with DNA and by recruiting and binding transcriptional cofactors.⁹ While it is presumed that *ARID1A* is a tumour suppressor gene because of widespread loss-of-function mutations found in human cancer samples,¹⁰ the effects of *ARID1A* loss in the pancreas and PDAC have generally not been well-characterised, with the exception of a recent study showing that pancreatic *Arid1a* loss led to

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Wang SC, Nassour I, Xiao S, et al. *Gut* 2019;68:1259–1270.

IPMN formation which may be mediated through *Sox9* expression and the mTor (mammalian target of rapamycin) pathway.¹¹

Protein synthesis is increased by almost all oncogenic signalling pathways including RAS, WNT- β -catenin and PI3K-mTOR.¹² Aberrantly increased translation supports the transformation of normal cells and the acquisition of various hallmark features, such as angiogenesis, altered metabolism and proliferation. The MYC pathway also increases translation. Previous studies have shown that protein synthesis driven by MYC can be oncogenic, and mitigation of the aberrant translation suppresses MYC's oncogenic activities.¹³

In this study, we characterised the effects of pancreas-specific *Arid1a* loss in mice. We found that pan-pancreatic *Arid1a* deletion synergised with an activating *Kras* mutation to induce IPMN. Using lineage-specific Cre expression systems, we found that *Arid1a* loss in pancreatic duct cells resulted in cystic dilation of ducts and PDAC, while heterozygous *Arid1a* deletion in the acinar compartment accelerated PanIN and PDAC formation. *Arid1a* loss in murine pancreata induced gene signatures associated with *Myc* activity and protein translation. Using human pancreatic ductal epithelial (HPDE) cells, we confirmed that *ARID1A* loss led to elevated protein expression mediated by MYC overexpression and a global increase in H3K27ac marks. Finally, we tested EZH2 inhibition as a way to blunt *Arid1a* loss-induced IPMN.

MATERIALS AND METHODS

Please see online supplementary materials and methods.

RESULTS

Arid1a loss is sufficient to initiate inflammation, PanIN and mucinous cysts

To determine the functional effects of *Arid1a* loss in pancreas, we generated *Ptf1a-Cre; Arid1a^{fl}* (referred henceforth as CA) mice. Exon 8 of *Arid1a* is flanked by loxP sites and tissue specificity was achieved with Cre under regulatory control by *Ptf1a*, which is a transcription factor that is expressed in all pancreas cell types starting around E9.5 (online supplementary figure S1A).^{14 15} These mice were viable, fertile and appeared grossly normal. *Arid1a* was deleted without alternatively spliced gene products or truncated proteins when bulk pancreata was examined with western blotting (online supplementary figure S1B).¹⁶ However, on closer examination of individual cellular compartments, we found that *Arid1a* deletion was complete in acinar cells, partial in ductal cells and almost none in the endocrine cells (figure 1A). When we used the *Rosa-LSL-tdTomato* reporter to track Cre expression, we found that tomato was expressed in essentially all cells, consistent with previous reports (online supplementary figure S1C).^{15 17} This pattern of *Arid1a* deletion by *Ptf1a-Cre* is consistent with results shown by other groups.¹¹

By 4 months of age, many CA mice developed acinar to ductal metaplasia (ADM, 12 of 14 mice, online supplementary figure S1D), which is a process where acinar cells respond to injury or stress by downregulating digestive enzymes, expressing duct-specific markers and taking on ductal phenotypes.¹⁸ ADM is reversible in wild-type mice on removal of the stress; however, ADM can progress to PanIN in the setting of oncogenic *Kras*.^{19–21} A significant proportion of CA mice also developed ductal lesions that were mucinous, as supported by Alcian blue staining, and appeared to be PanIN, based on morphology and claudin-18 positivity (11 of 14 mice, figure 1B). Four of 14 mice formed larger cysts with some lined by bland appearing epithelium, while others had papillary projections and mucinous components that

were claudin-18 positive (figure 1C). *ARID1A* expression in PanIN and cysts were mosaic within the same lesion (figure 1B, C).

Further characterisation of the cysts showed reactivation of embryonic factors PDX1 and HNF4A, which are associated with reprogramming of heretofore terminally differentiated cells into a dedifferentiated state capable of progressing down a neoplastic pathway (figure 1D).^{21–23} Inflammation has also been previously shown to be a key component of pancreatic reprogramming.^{21 24} In CA mice, there were occasional robust inflammatory responses as demonstrated by infiltration of CD45-positive lymphoid cells and marked fibrosis (online supplementary figure S1E). This is consistent with quantitative PCR data on bulk pancreata, where multiple chemokines and cytokines, such as *Il1b*, *Il7*, *Tnfa* and *Ccl2* were elevated (figure 1E). By 1 year of age, we did not observe any evidence of PDAC or significant progression of PanIN lesions. In addition, the cysts remained benign appearing, although reaching very large size in some instances, and there was also widespread adipocyte infiltration (online supplementary figure S1F). Thus, *Arid1a* loss in the pancreas was sufficient to initiate PanIN and simple mucinous cysts, but did not support further progression to higher grade dysplasia or frank carcinoma within 1 year.

Arid1a loss synergises with oncogenic *Kras* to accelerate IPMN formation

Activating *KRAS* mutations are found in more than 90% of human PanIN and PDAC samples and are thought to be the initiating driver event for PDAC.^{2 3 25} As a result, a large portion of *ARID1A* mutations in human PDAC are accompanied by *KRAS* mutations. IPMN have also been found to harbour *KRAS* mutations.¹ To determine the effects of concomitant *ARID1A* deletion and *KRAS* activation, we generated *Kras^{G12D}; Ptf1a-Cre; Arid1a^{fl}* mice (henceforth called 'KCA' mice, online supplementary figure S2A). By 8 weeks of age, *Kras^{G12D}; Ptf1a-Cre* (KC) mice had significant inflammation and developed numerous PanIN that were Alcian blue positive, as expected (figure 2A,B).²⁵ While KCA mice also developed inflammation and PanIN (online supplementary figure S2B), oncogenic *Kras* significantly accelerated the cyst phenotype seen in CA mice. Whereas only about 30% of CA mice developed macroscopic cysts that were occasionally mucinous or complex, all KCA mice had large mucinous cysts with papillary projections (figure 2A,B). As was the case in CA mice, the KCA cysts were mosaic for *ARID1A* expression (figure 2B).

There are two types of mucinous pancreatic cysts, both of which can progress to PDAC. Mucinous cystic neoplasms (MCN) are cyst-forming epithelial neoplasms composed of mucinous epithelium associated with ovarian-type stroma (expressing oestrogen and progesterone receptors), which do not communicate with the pancreatic ductal system, while IPMN are intraductal, grossly visible epithelial neoplasm of mucin-producing cells, arising in the main pancreatic duct or its branches, and usually exhibiting a papillary growth pattern.²⁶ Cysts in KCA mice demonstrated papillary projections and did not stain for oestrogen and progesterone receptors (online supplementary figure S2C). Analysis of the cyst fluid showed high amylase levels, suggesting a direct connection to the ductal system (figure 2C). Thus, histologic and biochemical analyses demonstrated that concurrent *Kras* activation and *Arid1a* deletion resulted in pancreatic mucinous cysts which resemble human IPMN, rather than MCN.

IPMN may be further categorised into four epithelial subtypes based on histomorphology and mucin expression patterns.²⁷ The intestinal and oncocytic subtypes progress to colloid and oncocytic adenocarcinomas, respectively, and have a more favourable

Figure 1 Conditional deletion of *Arid1a* in the pancreas induces inflammation, pancreatic intraepithelial neoplasia (PanIN) and mucinous cysts. (A) In wild-type mice, ARID1A was expressed in most acinar cells (red arrowheads), all duct cells ('D' adjacent) and all islet cells (asterisk). In *Ptf1a-Cre; Arid1a*^{fl/fl} (CA) mice, ARID1A was lost in all acinar cells (yellow arrowheads), some duct cells (red arrows point to lost, red arrowheads point to retained) and none of the islet cells. Sixteen-week-old CA mice formed (B) PanIN and (C) large cysts with flat to cuboidal epithelium with papillary projections (arrows) that were Alcian blue and claudin-18 positive. Both PanIN and cysts showed focal ARID1A positivity (arrowheads point to ARID1A-positive cells). (D) The cysts expressed embryonic factors PDX1 and HNF4a. (E) The pancreata of CA mice showed significant upregulation of chemokines and cytokines, as measured by quantitative PCR, n≥5, *P<0.05, **P<0.01.

outcome than PDAC not arising in these precursor lesions. Gastric and pancreaticobiliary subtypes tend to form tubular adenocarcinomas, which have significantly worse outcomes than colloid and oncocytic carcinomas, but still better than PDAC not arising in IPMN.²⁸ IPMN from KCA mice appeared to be predominantly of the gastric subtype, as most areas had short papillae and epithelium morphologically resembling gastric foveolar epithelium and did not express MUC1 or MUC2 (figure 2B,D). However, there were some occasional areas that resembled the pancreaticobiliary subtype, which is characterised by more interconnected and arborising papillae composed of cuboidal cells with little mucin (online supplementary figure S2D). We did not observe any lesions resembling the intestinal subtype and further confirmed by negative CDX2 immunohistochemistry (online supplementary figure S2E).

To determine if KCA cysts represent a faithful recapitulation of human disease, we asked if ARID1A expression was lost in human IPMN. We performed a retrospective review of our institutional surgical database and identified 35 patients

who underwent pancreatectomies from 2006 to 2016 and had IPMN identified on final pathology. In these patients, there were 28 gastric, 6 intestinal, 1 oncocytic and 10 pancreaticobiliary components (some patients had mixed IPMN containing more than one subtype). We performed immunohistochemistry for ARID1A and graded the expression as negative, low or high (online supplementary figure S2F). We found that 61% of gastric and 10% of pancreaticobiliary subtype IPMN had ARID1A null or low expression, whereas no intestinal type had ARID1A loss (figure 2E). Even when IPMN contained cells with no or low ARID1A staining, there were pockets of strong staining consistent with the mosaic expression pattern seen in KCA mice cysts (online supplementary figure S2G). These data show that ARID1A loss is present in human IPMN and highlights the clinical relevance of the KCA model.

While ARID1A has been considered a tumour suppressor, we recently showed that it has both context-dependent oncogenic and tumour-suppressive effects in liver cancer.²⁹ To determine the effect of *Arid1a* loss on PDAC formation, we generated

Figure 2 *Kras* activation synergises with *Arid1a* loss in the pancreas to induce intraductal papillary mucinous neoplasms (IPMNs). (A) *Kras*^{G12D}; *Ptf1a*-Cre (KC) mice had oedema, while *Kras*^{G12D}; *Ptf1a*-Cre; *Arid1a*^{fl/fl} (KCA) mice formed large pancreatic cysts. (B) KC mice showed significant inflammation and numerous pancreatic intraepithelial neoplasia. KCA mice formed large mucinous cysts with papillary projections that were mosaic for ARID1A (arrowhead points to ARID1A-positive cells). (C) KCA cyst fluid was amylase rich (normal serum amylase <10 U/L), suggesting a direct connection to the pancreatic ductal system, consistent with IPMN. n=4, error bars represent SEM. (D) KCA cysts with mucin expression patterns consistent with human gastric subtype IPMN. (E) Human gastric subtype (n=28) and pancreaticobiliary subtype (PB, n=10) IPMN showed areas with negative or low ARID1A staining, as compared with intestinal subtype (n=6). **P<0.01. (F) Kaplan-Meier curve estimating survival of *Kras*^{G12D}; *Trp53*^{fl/+}; *Ptf1a*-Cre mice that were *Arid1a*^{+/+}, *Arid1a*^{fl/+} or *Arid1a*^{fl/fl}.

Kras^{G12D}; *Trp53*^{fl/+}; *Ptf1a*-Cre (KPC) mice that were *Arid1a* wild-type, heterozygous or null. Surprisingly, we found no difference in survival between the three cohorts (figure 2F). While we noted cancer in all three KPC groups, KPC *Arid1a*-null mice often had massive cysts replacing almost all of the pancreas (online supplementary figure S2H). Thus, it was unclear if the cause of death for KPC *Arid1a*-null mice was cancer or mass effect from the large cysts.

***Arid1a* loss in pancreatic duct cells promotes cystic duct dilation and PDAC**

Since it was difficult to discern cancer-specific deaths in the KPC system, we hypothesised that we could isolate the IPMN phenotype using the inducible duct-compartment specific *Sox9*-CreER line (online supplementary figure S3A).³⁰ Mice were given

tamoxifen (TAM) after weaning at 3.5 to 4.5 weeks of age. We found that 3 to 4 months after induction *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{+/+} mice remained histologically bland, while *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{fl/fl} mice had mildly dilated pancreatic ducts (figure 3A,B). We observed a progressive increase in the calibre of pancreatic ducts at 26 weeks and then 52 weeks after TAM (figure 3B). At 52 weeks, we found that one of five *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{fl/fl} mice had a mucinous cystic lesion that exhibited focal mild epithelial papillary tufting, resembling the earliest signs of IPMN formation (figure 3A,C). *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{fl/fl} mice also occasionally had significant localised inflammation and PanIN (online supplementary figure S3B), but there was no evidence of frank carcinoma or dysplasia by 1 year after TAM. Three of 15 *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{+/+} mice

Figure 3 Phenotype of *Arid1a* deletion in pancreatic ductal cells. (A) Three to 4 months after tamoxifen (TAM) induction, both *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{+/+} and *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{fl/fl} mice formed small ductal lesions. Twelve months after TAM, *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{fl/fl} mice occasionally formed large cystic lesions, while *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{+/+} mice had only smaller lesions that most resembled pancreatic intraepithelial neoplasia. (B) *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{fl/fl} mice showed progressively enlarging ducts over time. At 12 weeks, n=12 and 9, at 26 weeks, n=6 and 10 and at 52 weeks, n=15 and 5 for *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{+/+} and *Arid1a*^{fl/fl} mice, respectively. *P<0.05, **P<0.01. (C) Lesions in *Kras*^{G12D}; *Sox9*-CreER; *Arid1a*^{fl/fl} mice were Alcian blue positive and mosaic for ARID1A (arrow to ARID1A-negative cells and arrowhead to ARID1A-positive cells, 'D' denotes duct/cyst lumens). (D) Serial section showed that ARID1A loss in *Sox9*-CreER; *Arid1a*^{fl/fl}; *ROSA26*-LSL-tdTomato (*Td*) corresponded to where tomato was expressed. Yellow dashed lines denote islets. (E) *Kras*^{G12D}; *Trp53*^{fl/+}; *Sox9*-CreER; *Arid1a*^{fl/fl} mice formed occasional pancreatic ductal adenocarcinoma that had sarcomatoid features (top panels) and incipient intraductal papillary mucinous neoplasm (bottom panels). Both lesions were ARID1A negative and tomato positive. ARID1A positivity were seen in stromal cells only.

had only very small foci of inflammation or ADM. There was no difference in proliferation in ductal cells (online supplementary figure S3C). To understand the phenotypic variation seen in the *Sox9*-CreER cohort, we performed lineage tracing using a *Rosa*-LSL-tdTomato (*Td*) reporter. We examined *Sox9*-CreER; *Td* mice 12 weeks after TAM and identified mosaic ARID1A expression that corresponded to tomato signal (figure 3D). In addition, we found that *Sox9*-CreER mice had 36% to 98% of the CK-19 positive ductal cells showing tomato positivity (online supplementary figure S3D).

To determine if tumour suppressor loss could accelerate cancer formation, we generated *Kras*^{G12D}; *Trp53*^{fl/+}; *Sox9*-CreER; *Td* mice that were *Arid1a* wild-type, heterozygous or null. A similar proportion of mice from all three genotypes developed soft tissue masses or ocular lesions that necessitated euthanasia, but no pancreas-related deaths were seen 1 year after TAM (online supplementary figure 3E). We found no pancreatic phenotypes in 14 *Kras*^{G12D}; *Trp53*^{fl/+}; *Sox9*-CreER; *Arid1a*^{+/+} mice and only small areas of inflammatory infiltrates in 2 of 16 *Kras*^{G12D}; *Trp53*^{fl/+}; *Sox9*-CreER; *Arid1a*^{fl/+} mice. Of the 12

Kras^{G12D}; *Trp53*^{fl/+}; *Sox9-CreER*; *Arid1a*^{fl/fl} mice, 2 had ADM or early PanIN and another 2 had cystic lesions (online supplementary figure 3F). Two other mice had firm, large pancreatic tail masses that were red on gross examination, suggesting tomato expression (figure 3E). On histologic examination, the masses were PDAC containing undifferentiated components with sarcomatoid features. In addition, they were ARID1A negative and tomato positive, confirming ductal origin (figure 3E). One of the two mice with PDAC had areas of duct dilation with some epithelial tufting suggestive of incipient IPMN (figure 3E), while the other had only PanIN-associated PDAC. In sum, these data show that *Arid1a* restrains tumourigenesis, either in the form of pre-IPMN lesions or PDAC, in ductal cells.

Heterozygous *Arid1a* loss accelerates PDAC formation

To determine the effects of *Arid1a* loss in the acinar compartment, we used the *Ptf1a*^{CreER} line to induce *Kras* and *Arid1a* mutations (online supplementary figure S4A).³¹ *Ptf1a*^{CreER} mice were given TAM between 3.5 and 4.5 weeks of age and we observed complete recombination in the acinar compartment without leakage into the duct cells or endocrine cells, consistent with previous reports (figure 4A,B and online supplementary figure S4B).^{31,32} We generated *Kras*^{G12D}; *Ptf1a*^{CreER} mice that were wild-type, heterozygous or null for *Arid1a* and observed inflammation, fibrosis and mucin-positive lesions consistent with PanIN in all three lines (figure 4C). In the *Arid1a* null mice, the PanINs lacked *Arid1a* expression, consistent with acinar origin (figure 4D). When we quantitated the amount of PanIN from each line by measuring the amount of claudin-18 positive lesions 16 weeks after TAM, we found *Arid1a* heterozygous mice had more PanIN than *Arid1a* wild-type mice (figure 4E). Similarly, when we made *Kras*^{G12D}; *Trp53*^{fl/+}; *Ptf1a*^{CreER} mice with all three *Arid1a* states, we found that *Arid1a* heterozygous mice had the worst survival (figure 4F). When we measured proliferation with Ki-67, we found no difference between the three groups (online supplementary figure S4C). While all three genotypes had moderately to poorly differentiated ductal adenocarcinomas, about 30% of mice in both *Arid1a* heterozygous and null groups had tumours with undifferentiated rhabdoid or sarcomatoid features (figure 4G). *Arid1a* null mice had an intermediate phenotype with respect to both PanIN quantity and overall survival.

Arid1a loss increases protein synthesis through the induction of MYC

To understand the downstream transcriptional effects of *Arid1a* deletion in the pancreas, we performed RNA sequencing of pancreata collected from CA mice and their wild-type littermates. We used gene set enrichment analysis and found that the *Myc* target gene network was the highest ranked among the 'Hallmark' gene sets, suggesting that *Arid1a* loss in CA mice pancreas induced increased MYC activity (figure 5A and online supplementary table 1).³³ We chose to focus on the ductal compartment to identify possible therapeutic targets for IPMN, as surgery is currently the only treatment option. We performed small-interfering RNA (siRNA) *ARID1A* knockdown in immortalised HPDE cells (figure 5B)³⁴ and found an increase in MYC protein expression (figure 5C). When we performed immunohistochemistry for c-MYC, we found only weak and patchy signals in PanIN of KC mice but intense signals in the cysts of KCA mice (figure 5D). Similarly, the cystic lesions in *Kras*^{G12D}; *Sox9-CreER*; *Arid1a*^{fl/fl} mice expressed c-MYC, while the duct cells in *Kras*^{G12D}; *Sox9-CreER*; *Arid1a*^{+/+} mice did not have any

expression (figure 5E). In both cohorts, there was very little to no signal in the acinar and islet compartments (online supplementary figures S5A,B).

To determine what pathways might be regulated by MYC, we analysed the RNA-seq data using the 'Molecular Signatures Database' and the top four highest ranked signatures were protein synthesis related (figure 6A and online supplementary table 1).³³ Because MYC directly regulates ribosomal protein transcription as one way to mediate increased translation, we measured ribosomal protein expression in CA pancreata using real-time quantitative PCR and found significant elevation in *Arid1a* null tissues (online supplementary figure S6A). To more directly determine if this was a result of acute *Arid1a* loss, we measured ribosomal protein expression in *Ptf1a-CreER*; *Arid1a*^{fl/fl} pancreata 1 week after TAM and also found increased expression (online supplementary figure S6B).

We next investigated whether increased expression of ribosomal proteins resulted in more or less protein synthesis and quantitatively assessed protein synthesis in the context of *Arid1a* loss. We used a fluorescent-labelling assay based on the incorporation of O-propargyl-puromycin (OPP), which is taken up by ribosomes and incorporated into new peptides. We found that *ARID1A* knockdown in HPDE cells significantly increased OPP incorporation, signifying increased translation (figure 6B and online supplementary figure S6C). Because MYC and mTOR drive essential signalling networks that integrate growth and proliferative signals to activate protein translation, we examined mTOR activity.³⁵ After *ARID1A* knockdown, there was no difference in mTOR activity, thus favouring MYC as the causative mechanism of protein synthesis activation (online supplementary figure S6D). To test if MYC was responsible for the increase in translation due to *ARID1A* loss, we used siRNA to partially knock down MYC in the setting of si*ARID1A* (figure 6C). When we measured protein synthesis, we found that returning MYC to baseline levels in the setting of *ARID1A* knockdown led to a reduction of OPP levels comparable to the levels seen in siMYC-treated cells (figure 6D and online supplementary figure S6E). This suggests that MYC, in part, mediates the control of protein translation by *ARID1A*.

ARID1A loss leads to increased activated enhancer/promoter marks

We next sought to understand the effects of *ARID1A* loss on chromatin activation. Using HPDE cells, we generated an *ARID1A*-null line using CRISPR/Cas9 (online supplementary figure S7). ChIP-seq was then performed against H3K27ac, which marks active enhancers and promoters. We found that *ARID1A* null cells had more peaks than cells with intact *ARID1A* (figure 7A). When we examined genes associated with MYC and protein translation signatures, which were the most upregulated gene networks identified from RNA-seq of CA pancreata (figure 5A and figure 6A), both also had significantly more peaks in *ARID1A* null cells (figure 7B,C). This shows that *ARID1A* loss led to increased activation of these target genes.

EZH2 inhibition does not abrogate *Arid1a* mutant IPMN

Since IPMN growth is associated with PDAC risk, therapies that slow IPMN progression would be highly desirable. Previous studies have suggested that SWI/SNF deficient tumours, including those with *ARID1A* mutations, are sensitive to inhibition of EZH2, which is the catalytic subunit of the Polycomb repressive complex 2.³⁶ Thus, we asked whether *Arid1a* mutant IPMN were susceptible to EZH2 inhibition. We first confirmed that trimethylated histone H3 lysine 27 (H3K27me3), a marker

Figure 4 Heterozygous *Arid1a* loss in acinar cells accelerates pancreatic intraepithelial neoplasia (PanIN) formation and shortens survival. (A) After tamoxifen, tomato expression in *Ptf1a^{CreER}; ROSA26-LSL-TdTomato (Td)* mice was restricted to acinar cells. None was seen in islets (yellow dashed outline) or ducts (yellow arrowheads). (B) After tamoxifen, ARID1A expression was lost in acinar cells but retained in duct and islet cells in *Ptf1a^{CreER}; Arid1a^{fl/fl}* mice. (C) After tamoxifen, *Kras^{G12D}; Ptf1a^{CreER}; Arid1a^{+/+}*, *Kras^{G12D}; Ptf1a^{CreER}; Arid1a^{fl/+}* and *Kras^{G12D}; Ptf1a^{CreER}; Arid1a^{fl/fl}* mice all developed PanIN. (D) PanIN in *Kras^{G12D}; Ptf1a^{CreER}; Arid1a^{fl/fl}* mice did not express ARID1A. (E) *Kras^{G12D}; Ptf1a^{CreER}; Arid1a^{fl/+}* formed more PanIN, $n=9$ for each group, $*P<0.05$. (F) *Kras^{G12D}; Trp53^{fl/+}; Ptf1a^{CreER}; Arid1a^{fl/+}* mice had worse survival than *Kras^{G12D}; Trp53^{fl/+}; Ptf1a^{CreER}; Arid1a^{+/+}* mice. $*P<0.05$. (G) *Kras^{G12D}; Trp53^{fl/+}; Ptf1a^{CreER}* mice with heterozygous and homozygous *Arid1a* loss developed components of undifferentiated pancreatic ductal adenocarcinoma with rhabdoid or sarcomatoid features.

of EZH2 activity, was highly expressed in KCA cysts (figure 8A). Next, we treated Capan-1 pancreatic cancer cells with the potent and specific EZH2 inhibitor EPZ011989 and confirmed that it was highly effective in reducing H3K27me3 levels (figure 8B).³⁷ We then performed abdominal MRI on 20 KCA mice at 3 to 4 weeks of age, when significant cyst burden was already present. Mice were randomised to vehicle or EPZ011989 and stratified based on gender and cyst volume. After 4 weeks of therapy, repeat MRIs were performed (figure 8C). We found that mice treated with EPZ011989 gained less weight than vehicle-treated mice (figure 8D) and that the compound effectively

reduced H3K27me3 levels in the pancreata of the treatment group (figure 8E). However, we found no difference in cyst volumes between the two groups (figure 8F). We also did not find any differences in proliferation and apoptosis in the cysts (online supplementary figure S8). Thus, *Arid1a* mutant IPMN epithelial cells did not respond to EZH2 inhibition *in vivo*.

DISCUSSION

SWI/SNF components are frequently mutated in a variety of cancers, including PDAC.³⁸ Although ARID1A is the most

Figure 5 *ARID1A* loss induces gene signatures associated with MYC activity. (A) Gene set enrichment analysis of RNA-seq of *Ptf1a-Cre; Arid1a^{fl/fl}* (CA) pancreata using the 'Hallmark' gene sets demonstrated that the MYC target gene signature was the most upregulated signature in CA mice. NES, normalised enrichment score; FDR, false discovery rate. (B) Western blot confirmed that siARID1A 1 and 2 were effective in knocking down ARID1A in human pancreatic ductal epithelial (HPDE) cells. (C) Western blot and quantification demonstrating that ARID1A knockdown induced MYC expression in HPDE cells. n=8, ***P<0.001. (D) PanIN in *Kras^{G12D}; Ptf1a-Cre; Arid1a^{+/+}* mice had patchy c-MYC expression, while cysts in *Kras^{G12D}; Ptf1a-Cre; Arid1a^{fl/fl}* mice stained intensely for c-MYC. (E) In *Kras^{G12D}; Sox9-CreER; Arid1a^{+/+}* mice, acinar, duct ('D' in duct lumen) and islet (asterisk) cells had very little c-MYC staining, while cysts from *Kras^{G12D}; Sox9-CreER; Arid1a^{fl/fl}* mice expressed some c-MYC.

commonly mutated SWI/SNF subunit in PDAC, the functional effects of *ARID1A* alterations are unclear.^{2,3} To clarify the effects of *ARID1A* mutations in pancreatic neoplasms, we generated pancreas-specific *Arid1a* deficient mice using the *Ptf1a-Cre* system that resulted in complete *Arid1a* loss in acini, mosaic *Arid1a* deletion in duct cells and complete *Arid1a* retention in the islets. This suggests that in the ductal and endocrine compartments *Arid1a* was either required during development or its locus is inaccessible to Cre recombinase. We found that *Arid1a* loss alone was sufficient to generate PanIN and mucinous cysts that re-expressed progenitor markers such as PDX1 and HNF4A in a manner similar to that seen in pancreatitis and *Kras* activation.^{21 22 32 39} Our work shows that *ARID1A* activity was necessary to maintain terminal differentiation of the pancreatic epithelium, and its loss resulted in a more dedifferentiated state that allowed neoplastic transformation, consistent with results recently reported by Kimura *et al.* and Livshits *et al.*^{11 40} The concept that *ARID1A* is permissive for the process of tissue differentiation is also consistent with our previous work in the liver, where *Arid1a* loss resulted in downregulation of liver gene expression programmes involving coagulation, bile acid metabolism and xenobiotic metabolism.¹⁶ In this way, *ARID1A* joins a group of other transcription factors and epigenetic modifiers, such as *PTF1A*, *SOX9* and *BRG1*, as important players in maintaining pancreatic identity.^{32 39 41 42}

We found that concurrent *Kras* activation and *Arid1a* loss led to IPMN formation, consistent with the findings of Kimura

*et al.*¹¹ These lesions were predominantly of gastric subtype, but there were areas of pancreaticobiliary epithelium. Because we also observed *ARID1A* loss in human gastric and pancreaticobiliary IPMN resection samples, the cysts that formed from murine *Arid1a* deletion appeared to recapitulate human disease. Both our findings and those of Kimura *et al.* showed that only a small subset of mice with duct-specific *Kras* activation and *Arid1a* deletion developed dilated cyst with dysplasia. We extended this work by also incorporating the loss of one *Trp53* allele and found that a subset of mice developed PDAC. It is likely that additional tumour suppressor loss or activation of oncogenes such as *GNAS* and *RNF43*, the most commonly mutated genes in IPMN, play a more catalytic role in driving duct cells into IPMN.⁴³ In addition, other non-ductal cell autonomous effects may be required. For example, in the embryonic *Ptf1a-Cre* model, there was a significant inflammatory response induced by the activated *Kras* mutation in the acinar cells. Whether inflammation can accelerate IPMN formation is a topic that requires further study.

We also showed that *Arid1a* has tumour-suppressive effects in acinar cells. We observed that heterozygous *Arid1a* loss in conjunction with activated *Kras* in acini resulted in increased PanIN formation and reduced survival. Previous work by Hosada *et al.* that identified *ARID1A* mutations in high-grade PanIN hinted at *ARID1A*'s tumour-suppressive effects in the PanIN-PDAC axis.⁴⁴ We also found that *Arid1a* loss led to tumours that contained components of undifferentiated PDAC

Figure 6 *ARID1A* loss induces MYC-mediated increase in protein synthesis. (A) Gene set enrichment analysis of RNA-seq of *Ptf1a-Cre; Arid1a^{fl/fl}* (CA) mice pancreata using the 'Molecular Signatures Database' demonstrated that the top four upregulated signatures in CA mice were associated with protein translation. NES, normalised enrichment score; FDR, false discovery rate. (B) Human pancreatic ductal epithelial (HPDE) cells were treated with O-propargyl-puromycin (OPP), which were incorporated into nascent peptides, labelled with fluorescence and quantified with fluorescence activated cell sorting (FACS). Representative FACS plot (left) and quantification (right) are shown. HPDE cells were treated siScramble (n=7), siARID1A 1 (n=6) and siARID1A 2 (n=6). Cycloheximide (CHX) is a translation inhibitor and served as a negative control for the assay in cells treated with siScramble (n=2). *P<0.05, **P<0.01. (C) Western blot demonstrating partial knockdown of MYC with siMYC in HPDE cells. (D) HPDE cells were treated with OPP and treated with siScramble (n=8), siARID1A (n=3), siMYC 1 (n=7) and siARID1A and siMYC 1 (n=3). Quantification of relative fluorescence is shown. *P<0.05, **P<0.01.

Figure 7 *ARID1A* loss leads to increased H3K27ac marks. Metagenes plot and heatmap of H3K27ac sites in human pancreatic ductal epithelial cells that were wild type (WT) or null (KO) for *ARID1A* for the given gene sets. TSS, transcription start site. (A) 'All genes'. (B) 'Hallmark MYC Targets V2' signature from Gene Set Enrichment Analysis (GSEA). (C) 'Reactome Peptide Chain Elongation' signature from GSEA.

Figure 8 EZH2 inhibition does not block intraductal papillary mucinous neoplasm growth in *Kras^{G12D}; Ptf1a-Cre; Arid1a^{fl/fl}* (KCA) mice. (A) Immunohistochemistry showing KCA murine cysts expressed high levels of H3K27me3. (B) Western blot showing that Capan-1 cells treated with EPZ011989 had decreased levels of H3K27me3. (C) Treatment plan, n=10 for each arm (vehicle and EPZ011989). Day 1 was defined by when the first dose was given. (D) Mice treated with EPZ011989 had a lower rate of weight gain than mice treated with vehicle. (E) Pancreata from the treatment group had decreased H3K27me3 levels on western blot. (F) Representative coronal section of MRI from vehicle and EPZ011989 treated KCA mice before and after treatment (arrowheads pointing to cysts, which were fluid filled, thus showing up as white signal on T2 weighted MRI). There was no difference in the change in volume after EPZ011989 treatment. AU, arbitrary unit. BID, two times daily.

with rhabdoid and sarcomatoid features. These results are in line with several recent studies linking loss of *Smarchb1*, another SWI/SNF component, to a more mesenchymal or dedifferentiated PDAC phenotype.^{45 46} Interestingly, the *Arid1a* null mice had a phenotype more similar to *Arid1a* wild-type mice in terms of PanIN formation and long-term survival. This likely speaks to the complicated context-dependent role of *Arid1a* in cancer biology consistent with what we had previously explored in the liver. There, we found that *Arid1a* was required in normal tissues to initiate cancer (ie, *Arid1a* was pro-tumorigenic) but in established cancers, *Arid1a* loss led to more aggressive cancer phenotypes (ie, *Arid1a* was tumour suppressive).²⁹

While the PanIN to PDAC pathway is well established, the true cell of origin for human PDAC remains unclear. Using the transgenic mouse model, multiple groups have demonstrated that the acinar compartment can give rise to PanIN and PDAC in the setting of activating *Kras* mutations.^{19–21 47} Gidekel Friedlander *et al.* showed that, in the setting of chronic injury, endocrine cells were also capable of giving rise to PanIN.⁴⁸ Our data showing

that PanIN-associated PDAC arose from *Kras^{G12D}; Trp53^{fl/+}; Sox9-CreER; Arid1a^{fl/fl}* mice supports recent work by Lee *et al.*, who demonstrated that duct cells were capable of giving rise to PanIN and PDAC, using the *Sox9-CreER* line, and Bailey *et al.*, who generated PDAC using the *Hnf1b-CreERT* line.^{49 50} Similarly, while *Sox9-CreER*-induced *Arid1a* loss led to cyst dilation, likely originating from the ductal compartment, this does not exclude the possibility that these lesions formed via a progenitor/ADM-like state, since a small percentage of acinar cells were labelled by *Sox9-CreER*.³²

While *ARID1A* loss of function mutations have been identified in ~10% of PDAC samples in multiple large sequencing studies,^{2 3} the mutational profiles of IPMN are currently being delineated with next-generation sequencing.^{51–53} While some studies found *ARID1A* mutations in only a small number of resected IPMN,⁵⁴ Tan *et al.* showed that *ARID1A* was mutated in approximately 10% of all IPMN samples and was one of the more commonly mutated genes.⁴ In addition, a recent study by Suenaga *et al.* found that about 15% of patients with IPMN

containing high-risk features had *ARID1A* mutations detectable in pancreatic juice.⁵ Other mechanisms for *ARID1A* downregulation are likely to be involved as we found a significant proportion of resected IPMN with areas expressing little or no *ARID1A*. Similarly, Kimura *et al.* found that in their resected IPMN cohort, 22% of the samples lacked *ARID1A* on the protein level.¹¹

Mechanistically, we found that genes involved in protein synthesis were overexpressed in *Arid1a*-deficient pancreata and that *ARID1A* knockdown in immortalised human pancreatic duct cells resulted in increased protein translation. In addition, we observed that *ARID1A* knockdown induced *MYC* expression, and concurrent knockdown of *ARID1A* and *MYC* in HPDE cells abrogated the increased translation, indicating that *ARID1A* loss operates, at least in part, through *MYC* activation. Intriguingly, both we and Kimura *et al.* observed that there was no increased proliferation in the *Arid1a*-null duct cells to explain the increase in duct size.¹¹ They had speculated that dilated cysts must thus occur due to mucin overproduction. Our finding that *Arid1a* loss led to increased protein translation supports that theory of IPMN formation. Based on the observation that mucinous cysts developed in mice with only *Arid1a* loss, perhaps *Arid1a* loss can be an initiating event that results in increased protein/mucin synthesis that mechanically increases duct size based on mass effect. A future acquisition of a driver mutation in genes such as *KRAS*, *GNAS* or *RNF43* then leads to transformation. This hypothesis would be consistent with the fact that many IPMN do not transform and progress to cancer.

The functional connection we identified between *Arid1a* loss and *Myc* expression is consistent with previous reports. First, Nagl *et al.* showed that the *Myc* promoter was a direct target of the SWI/SNF complex.⁵⁵ Second, Genovese *et al.* reported that the loss of *Smad3*, another component of the SWI/SNF complex, in PDAC cell lines activated *Myc* programmes that led to elevated protein synthesis and increased the aggressiveness of cancer cells.⁴⁵ Significantly, the increased protein synthesis rendered *Smad3* deficient cancer cell lines particularly sensitive to drugs that targeted the proteostatic stress response machinery, suggesting that this strategy may also be effective in *ARID1A* null IPMN and warrants further study. Furthermore, we found that the increase in protein production induced by *ARID1A* loss was not accompanied by activated mTOR signalling, which is an important activator of translation. This suggests that *ARID1A* loss may activate a translation programme specific to *MYC* activity. In addition, we also found that *ARID1A* loss led to increased H3K27ac marks at the loci of *MYC* targets and involved in protein translation, signifying increased transcriptional activity at these sites.

While increased protein synthesis has been considered a general hallmark of rapidly proliferating malignant cells, recent reports have demonstrated that elevated translation is necessary in only certain oncogenic contexts. Barna *et al.* showed that while elevated protein synthesis is required for *Myc*-driven lymphoma formation, moderating translation did not affect lymphomagenesis in the *Trp53*^{-/-} background. These data suggest that protein synthesis is a specific requirement for *Myc* oncogenesis and not a function of carcinogenesis as a whole.¹³ However, since *ARID1A* and SWI/SNF potentially influence loci across the entire genome, it is likely that *ARID1A* mediates pancreatic neoplasm formation and progression through a variety of other pathways in addition to ones involving protein synthesis. Further studies will be required to confirm that aberrant translation is a specific necessity for cyst formation resulting from *Arid1a* deletion and to elucidate additional pathways that are preferentially activated by SWI/SNF loss to drive cyst formation.

The survival rate for patients with PDAC remains dismal, and more than 90% of patients will die of the disease.¹ One strategy to improve outcomes is to intervene in patients with premalignant lesions, such as IPMN. Conversion from premalignancy to carcinoma significantly worsens survival as demonstrated by the fact that 50% of patients who undergo resection of localised disease still die within 2 years from recurrent disease.⁵⁶ However, there are no medical treatments for IPMN, and the only intervention available is prophylactic pancreatectomy, which carries morbidity and risk of death. Previous studies have described an antagonistic relationship between the SWI/SNF and PRC2 complexes, prompting preclinical and early phase clinical tests.⁵⁷ However, we found no difference in cyst size, or apoptosis or proliferation in cyst epithelium after treating a cohort of KCA mice with a potent EZH2 inhibitor. One possible explanation for this negative finding comes from the work of Kim *et al.*, who found that in *KRAS* gain-of-function mutants EZH2 structural inhibition, rather than functional inhibition of the catalytic site, was essential to induce apoptosis.⁵⁸

In conclusion, we have identified *ARID1A* as a pancreatic tumour suppressor that acts by repressing *KRAS*-induced PanIN and IPMN formation. *ARID1A* loss leads to increased *MYC* expression, elevated protein synthesis and a globally activated chromatin state. Continued insights into the mechanisms that drive premalignant PDAC lesions may lead to novel therapeutic strategies against this lethal disease.

Author affiliations

¹Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA

²Children's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

³Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, Texas, USA

⁴Howard Hughes Medical Institute, Chevy Chase, Maryland, USA

⁵Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

⁶Epizyme, Inc., Cambridge, Massachusetts, USA

⁷Department of Pathology, Stanford University, Stanford, California, USA

Acknowledgements We thank Dr. Rolf Brekken for sharing various reagents and mouse lines and critical reading of the manuscript, John Shelton and the UTSW Histology/Pathology Core for histology assistance, and the Children's Research Institute Sequencing Core for sequencing.

Contributors SCW, IN and HZ conceived of and designed the experiments. SCW, IN, SX, SZ, LHN, J-CC performed experiments. LP and JS performed histological evaluations. XL and JL performed bioinformatics analyses. SCW and IN performed statistical calculations. SD provided key reagent and helped design the experiment. All authors contributed to data interpretation. SCW, IN and HZ wrote the manuscript.

Funding SCW was supported by the UT Southwestern Disease Oriented Clinical Scholarship, American College of Surgeon Faculty Research Fellowship, American Cancer Society Institutional Research Grant, and National Institutes of Health (NIH) 1K08CA222611 grant. IN was supported by the Alpha Omega Alpha Honor Medical Society, ChiRhoClin and the National Center for Advancing Translational Sciences of the NIH UL1TR001105. XS was supported by the Hamon Center for Regenerative Science and Medicine at UT Southwestern Medical Center. JL was supported by the Cancer Prevention Research Institute (CPRI) (RP150596). HZ was supported by a Burroughs Wellcome Career Medical Award, CPRI New Investigator Grant (R1209), CPRI Early Translation Grant (DP150077), NIH/NIDDK R01DK111588, and a Stand Up To Cancer Innovative Research Grant (SU2C-AACR-IRG 10-16). Stand Up To Cancer is a program of the Entertainment Industry Foundation and its research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C.

Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Competing interests SD is an employee and stockholder of Epizyme.

Patient consent Not required.

Ethics approval Institutional Review Board.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. *N Engl J Med Overseas Ed* 2014;371:1039–49.
- Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016;531:47–52.
- Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. *Cancer Cell* 2017;32:185–203.
- Tan MC, Basturk O, Brannon AR, et al. GNAS and KRAS Mutations define separate progression pathways in intraductal papillary mucinous neoplasm-associated carcinoma. *J Am Coll Surg* 2015;220:845–54.
- Suenaga M, Yu J, Shindo K, et al. Pancreatic juice mutation concentrations can help predict the grade of dysplasia in patients undergoing pancreatic surveillance. *Clin Cancer Res* 2018;24:2963–74.
- Kwon H, Imbalzano AN, Khavari PA, et al. Nucleosome disruption and enhancement of activator binding by a human SWI/SNF complex. *Nature* 1994;370:477–81.
- Imbalzano AN, Kwon H, Green MR, et al. Facilitated binding of TATA-binding protein to nucleosomal DNA. *Nature* 1994;370:481–5.
- Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. *Nat Rev Cancer* 2011;11:481–92.
- Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? *Cancer Discov* 2013;3:35–43.
- Jones S, Wang TL, Shih I, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science* 2010;330:228–31.
- Kimura Y, Fukuda A, Ogawa S, et al. ARID1A Maintains differentiation of pancreatic ductal cells and inhibits development of pancreatic ductal adenocarcinoma in mice. *Gastroenterology* 2018;155:194–209.
- Truitt ML, Ruggero D. New frontiers in translational control of the cancer genome. *Nat Rev Cancer* 2016;16:288–304.
- Barna M, Pusic A, Zollo O, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. *Nature* 2008;456:971–5.
- Gao X, Tate P, Hu P, et al. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. *Proc Natl Acad Sci U S A* 2008;105:6656–61.
- Kawaguchi Y, Cooper B, Gannon M, et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. *Nat Genet* 2002;32:128–34.
- Sun X, Chuang JC, Kanchwala M, et al. Suppression of the SWI/SNF Component arid1a promotes mammalian regeneration. *Cell Stem Cell* 2016;18:456–66.
- Madisen L, Zwingman TA, Sunkin SM, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat Neurosci* 2010;13:133–40.
- Murtaugh LC, Keefe MD. Regeneration and repair of the exocrine pancreas. *Annu Rev Physiol* 2015;77:229–49.
- De La O JP, Emerson LL, Goodman JL, et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. *Proc Natl Acad Sci U S A* 2008;105:18907–12.
- Habbe N, Shi G, Meguid RA, et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. *Proc Natl Acad Sci U S A* 2008;105:18913–8.
- Morris JP, Cano DA, Sekine S, et al. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. *J Clin Invest* 2010;120:508–20.
- Jensen JN, Cameron E, Garay MV, et al. Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration. *Gastroenterology* 2005;128:728–41.
- Harries LW, Locke JM, Shields B, et al. The diabetic phenotype in HNF4A mutation carriers is moderated by the expression of HNF4A isoforms from the P1 promoter during fetal development. *Diabetes* 2008;57:1745–52.
- Guerra C, Schuhmacher AJ, Cañamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. *Cancer Cell* 2007;11:291–302.
- Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* 2003;4:437–50.
- Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. *Pancreatol* 2006;6:17–32.
- Adsay V, Mino-Kenudson M, Furukawa T, et al. Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract: recommendations of verona consensus meeting. *Ann Surg* 2016;263:162–77.
- Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. *Gut* 2011;60:1712–20.
- Sun X, Wang SC, Wei Y, et al. Arid1a has context-dependent oncogenic and tumor suppressor functions in liver cancer. *Cancer Cell* 2017;32:574–89.
- Kopp JL, Dubois CL, Schaffer AE, et al. Sox9+ ductal cells are multipotent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas. *Development* 2011;138:653–65.
- Pan FC, Bankaitis ED, Boyer D, et al. Spatiotemporal patterns of multipotentiality in Ptf1a-expressing cells during pancreas organogenesis and injury-induced facultative restoration. *Development* 2013;140:751–64.
- Kopp JL, von Figura G, Mayes E, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. *Cancer Cell* 2012;22:737–50.
- Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102:15545–50.
- Ouyang H, Mou L, Luk C, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. *Am J Pathol* 2000;157:1623–31.
- Laplanche M, Sabatini DM. mTOR signaling in growth control and disease. *Cell* 2012;149:274–93.
- Bitler BG, Aird KM, Garipov A, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. *Nat Med* 2015;21:231–8.
- Campbell JE, Kuntz KW, Knutson SK, et al. EPZ011989, A potent, orally-available ezh2 inhibitor with robust in vivo activity. *ACS Med Chem Lett* 2015;6:491–5.
- Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. *Nat Genet* 2013;45:592–601.
- Krah NM, De La O JP, Swift GH, et al. The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma. *Elife* 2015;4:e07125.
- Livshits G, Alonso-Curbelo D, Morris JP, et al. Arid1a restrains Kras-dependent changes in acinar cell identity. *Elife* 2018;7:7.
- von Figura G, Fukuda A, Roy N, et al. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. *Nat Cell Biol* 2014;16:255–67.
- Roy N, Malik S, Villanueva KE, et al. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. *Genes Dev* 2015;29:658–71.
- Stark A, Donahue TR, Reber HA, et al. Pancreatic cyst disease. *JAMA* 2016;315:1882–12.
- Hosoda W, Chianichiano P, Griffin JF, et al. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. *J Pathol* 2017;242:16–23.
- Genovese G, Carugo A, Tepper J, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. *Nature* 2017;542:362–6.
- Agaimy A, Haller F, Frohner J, et al. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. *Mod Pathol* 2015;28:248–60.
- Fukuda A, Wang SC, Morris JP, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. *Cancer Cell* 2011;19:441–55.
- Gidekel Friedlander SY, Chu GC, Snyder EL, et al. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. *Cancer Cell* 2009;16:379–89.
- Lee AYL, Dubois CL, Sarai K, et al. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. *Gut* 2018.
- Bailey JM, Hendley AM, Lafaro KJ, et al. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. *Oncogene* 2016;35:4282–8.
- Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. *Sci Transl Med* 2011;3:92ra66–6.
- Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. *Proc Natl Acad Sci U S A* 2011;108:21188–93.
- Furukawa T, Kuboki Y, Tanji E, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. *Sci Rep* 2011;1:161.
- Pea A, Yu J, Rezaee N, et al. Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. *Ann Surg* 2017;266:133–141.
- Nagl NG, Wang X, Patsialou A, et al. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. *Embo J* 2007;26:752–63.
- Allen PJ. Pancreatic adenocarcinoma: putting a hump in survival. *J Am Coll Surg* 2007;205:S76–S80.
- Kadoch C, Copeland RA, Keilhack H. PRC2 and SWI/SNF chromatin remodeling complexes in health and disease. *Biochemistry* 2016;55:1600–14.
- Kim KH, Kim W, Howard TP, et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. *Nat Med* 2015;21:1491–6.